Orforglipron and Encorafenib: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Encorafenib
Orforglipron
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Reduced orforglipron exposure and reduced efficacy of orforglipron
Interaction Deep Dive
Avoid concomitant use of orforglipron with strong CYP3A4 inducers as it may reduce orforglipron exposure, which may reduce the effectiveness of orforglipron. In drug interaction studies, concomitant use of orforglipron with carBAMazepine (strong CYP3A4 inducer) (300 mg twice daily) reduced the orforglipron AUC by 82%, and Cmax by 55%1.
Why it happens (mechanism)
Induction of CYP3A4-mediated metabolism of orforglipron
Literature reports
1 report — tap to read
a) In drug interaction studies, concomitant use of orforglipron with carBAMazepine (strong CYP3A4 inducer) (300 mg twice daily) reduced the orforglipron AUC by 82%, and Cmax by 55% 1.
Common questions
Can I take Orforglipron and Encorafenib together?
Reduced orforglipron exposure and reduced efficacy of orforglipron Always confirm with your pharmacist or prescriber before making any change.
How serious is the Orforglipron and Encorafenib interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Questions for your pharmacist
- Does my dose of Orforglipron or Encorafenib need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: FOUNDAYO™ oral tablet, orforglipron oral tablet. Lilly USA LLC, Indianapolis, IN, 2026. DailyMed
Keep reading about Encorafenib
Keep reading about Orforglipron
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist